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Cancer cells rely heavily on molecular chaperones, such as heat shock protein 90 (HSP90), 
and their co-chaperones. The development of HSP90 inhibitors is an attractive therapeutic 
approach that has the potential to affect multiple hallmarks of cancer. Such approach is 
particularly needed for tumors that carry large mutational burdens, including cutaneous 
squamous cell carcinomas (cSCC). We previously identified sulfoxythiocarbamate S-4 as an 
HSP90 inhibitor. In this study, we investigated the mechanism(s) by which S-4 compromises 
the viability of human cSCC cells. S-4 inhibits HSP90 and causes depletion of its clients 
HER2, a tyrosine kinase oncoprotein, and Bcl-2, an anti-apoptotic protein. The decrease in 
Bcl-2 is accompanied by cytochrome c release from mitochondria into the cytoplasm, 
suggesting apoptosis. In the surviving cells, depletion of the HSP90 clients cyclin D and 
CDK4 by S-4 prevents phosphorylation of the retinoblastoma	protein Rb and the release of 
transcription factor E2F, inhibiting G1-S cell cycle progression and cell division. These 
findings illustrate the comprehensive effectiveness of S-4 and encourage future development 
of compounds of this type for cancer prevention and treatment.  
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1. Introduction 
Heat shock protein 90 (HSP90) facilitates the correct folding and stability of a broad 
range of ~200 “client” proteins. (Taipale et al., 2010).  In cancer cells, HSP90 acts as a 
molecular chaperone for numerous oncogenic proteins and is essential for their activity and 
stability, particularly for those that are activated by mutation(s) or overexpression (Taldone et 
al., 2019; Whitesell and Lindquist, 2005). Thus, the development of inhibitors of HSP90 is an 
attractive strategy for cancer treatment (Trepel et al., 2010). Moreover, inhibition of HSP90 
shows promise for overcoming drug resistance that frequently limits successful cancer 
treatment, and for improving the efficacy of immunotherapy (Kryeziu et al., 2019). 
Cutaneous squamous cell carcinomas (cSCC), which are most commonly caused by 
recreational or occupational exposure to solar ultraviolet radiation (UVR), represent some of 
the most frequently diagnosed keratinocyte skin cancers, and the most highly mutated human 
malignancies. Although surgical excision, radiotherapy, and chemotherapy are effective 
against primary tumors, mortality for metastatic cSCC is as high as 70% (Burton et al., 2016). 
Comprehensive characterization studies of the genomic changes that drive development of 
cSCC in both humans and mice have revealed mutations in numerous oncogenes and tumor 
suppressor genes (Chitsazzadeh et al., 2016; Knatko et al., 2017; South et al., 2014), implying 
that therapies that target individual oncoproteins are unlikely to succeed, and global 
approaches are needed for the prevention and treatment of these cancers. Topical treatment of 
the skin of mice with the HSP90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin (17-
AAG) prevents the development of UVR-induced SCC, and is accompanied by a decrease in 
UVR-induced hyperplasia of the skin, and lower levels of a number of HSP90 client proteins 
without any local or systemic toxicity (Singh et al., 2015). These preclinical observations 
suggest that HSP90 inhibitors could be developed as topical agents for prevention of cSCC. 
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Using click chemistry, we previously found that the mildly electrophilic compound 
sulfoxythiocarbamate alkyne (STCA) binds to cysteine residues of Kelch-like ECH 
associated protein 1 (Keap1) (Ahn et al., 2010) to activate transcription factor nuclear factor 
erythroid 2 p45-related factor 2 (Nrf2), which in turn regulates the expression of a network of 
genes encoding cytoprotective proteins (Cuadrado et al., 2019). Genetic or pharmacologic 
activation of Nrf2 is protective against UVR-induced skin damage in mice and humans 
(Dinkova-Kostova et al., 2008; Knatko et al., 2015; Talalay et al., 2007), and reduces the 
development of cSCC caused by chronic exposure to solar-simulated UVR in mice (Knatko 
et al., 2016; Knatko et al., 2015), suggesting that pharmacologic Nrf2 activators are good 
candidates for photoprotective agents. A mass spectrometry-based proteomic approach 
showed that in addition to Keap1, STCA also binds to HSP90 in cells (Ahn et al., 2010; 
Zhang et al., 2011) and covalently modifies cysteine residues of purified recombinant HSP90 
in vitro, forming stable thiocarbamate adducts (Zhang et al., 2014). A cell-based screen of 19 
sulfoxythiocarbamate derivatives identified compound S-4 (Fig. 1A) as an HSP90 inhibitor, 
which destabilizes multiple HSP90 client proteins and decreases proliferation of breast cancer 
cells (Zhang et al., 2014). Among the HSP90 clients downregulated by S-4 in these cells was 
HER2 (gene name ERBB2). Curiously, molecular similarities, including mutations in HER2, 
have been observed between cSCC and specific subtypes of breast cancer, suggesting 
common molecular vulnerabilities (Chitsazzadeh et al., 2016). In the present study we 
address the mechanism(s) by which S-4 compromises cell viability using early passages of 






2. Materials and Methods 
2.1. Materials 
AUY922 (NVP-AUY922) was from ApexBio Technology. S-4 was synthesized as described 
(Zhang et al., 2014). The identity and purity (>94%) of S-4 were determined by 1H- and 13C-
NMR spectroscopy and liquid chromatography-mass spectrometry (LC-MS). Spectra are 
shown in Supplemental Fig. 1A. For cell culture experiments, AUY922 was dissolved in 
DMSO and S-4 was dissolved in acetonitrile. Both solutions were then diluted (1:1000) in the 
cell culture medium. The concentration of solvent in the cell culture medium was maintained 
at 0.1%. All other general chemicals and reagents were of analytical grade and obtained from 
Sigma-Aldrich. 
 
2.2. HSP90β expression and purification 
A plasmid encoding human GST-HSP90β fusion protein (Zhang et al., 2014) was 
transformed into E. coli BL21 (DE3) codon plus cells.  Cells were grown at 37°C in LB 
media until OD600 of 0.6-0.8, then induced at 37°C with isopropyl β-d-1-
thiogalactopyranoside (IPTG, 1 mM) for 4 h. Cell pellets were collected by centrifugation 
and sonicated in PBS. Cell lysates were clarified by centrifugation at 17,700 x g. The 
supernatant was loaded onto Glutathione Sepharose 4 FF (GE healthcare) for affinity 
purification. Bound protein was cleaved by precision-protease at 4°C overnight, and HSP90β 
was collected in the flow-through fraction. Protein purity was confirmed following SDS-
PAGE and Coomassie blue staining.         
    
2.3. Cysteine modification of HSP90β by S-4  
Purified HSP90β was dialyzed against 40 mM HEPES, pH 7.5, 20 mM KCl, and 1 
mM tris(2-carboxyethyl)phosphine (TCEP). Dialysed Hsp90β (1 µM) was incubated with S-4 
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(15 µM) or DMSO (vehicle for S-4) in 50 µl of buffer (40 mM HEPES, pH 7.5, 20 mM KCl, 
1 mM TCEP), at room temperature, for 2 h. The samples were then mixed with NuPAGE™ 
LDS Sample Buffer (Thermo Scientific), incubated at room temperature for 30 min, and gel-
purified using NuPAGE™ 4-12% Bis-Tris gel and NuPAGE™ MOPS SDS Running Buffer 
(Thermo Scientific). The gel was stained with InstantBlue™ (Expedeon) and the Hsp90β 
band was excised, reduced with TCEP, alkylated with 2-iodoacetamide (IAA), in-gel 
digested with trypsin, and subjected to analysis by liquid chromatography-mass spectrometry 
(LC-MS) on an Orbitrap Velos equipped with Easy spray source and Ultimate 3000 UPLC. 
 
2.4. Cell culture 
The establishment of the human cutaneous squamous cell carcinoma cell lines SCC 
IC1 and SCC IC12 has been previously described (Proby et al., 2000). Cell lines were 
cultured in RM+ media with the following composition: a mixture of DMEM:Ham's F12 
(3:1) (Thermo Scientific) media supplemented with 10% fetal bovine serum (FBS, Thermo 
Scientific), 0.4 µg/ml hydrocortisone (Sigma), 5 µg/ml insulin (Sigma), 10 ng/ml epidermal 
growth factor (EGF, Serotec), 5 µg/ml transferrin (Sigma), 8.4 ng/ml cholera toxin (Sigma) 
and 13 ng/ml liothyronine (Sigma). Normal Human Keratinocyte (NHK) cells were isolated 
from breast or abdominal skin of human subjects after informed consent, initially grown in 
the presence of a mitotically inactivated NIH3T3 fibroblast feeder layer as described 
(Rheinwald, 1980), and cryopreserved. Frozen NHK cells were rapidly thawed in a 37°C 
water bath and cultured overnight in RM- (same composition as RM+, but without EGF) 
media. On the next day, the media was replaced with RM+ media. Cells were maintained in a 
humidified atmosphere at 37°C and 5% CO2. 
 
2.5. ATP-binding assay 
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SCC IC1 cells (0.5×106) growing in 6-cm dishes were treated for 24 h with either 
0.1% (v/v) acetonitrile (vehicle for S-4), 7.5 µM S-4, 0.1% DMSO (vehicle for AUY922) or 
0.1 µM AUY922. Using a scraper, cells were collected into 300 µl of lysis buffer (10 mM 
Tris pH 7.5, 150 mM NaCl, 0.25% NP40, with one protease inhibitor tablet (Roche) per 10.0 
ml of buffer), and the cell suspension was frozen, thawed, and lysed for 30 min at 4°C. ATP-
agarose beads (Jena Bioscience, AC-101S) were washed with incubation buffer (10 mM Tris 
pH 7.5, 150 mM NaCl, 20 mM MgCl2, 0.05% NP40, 1 mM DTT). The beads suspension (30 
µl) was mixed with 200 µg of protein in a final volume of 1.25 ml of buffer, and incubated 
rotating overnight at 4°C. The beads were then collected by centrifugation and washed three 
times with incubation buffer. Following addition of 10 µl of sodium	dodecyl	sulfate	(SDS) 
loading buffer and 40 µl of incubation buffer, the samples were heated at 100°C for 5 min. 
The beads were pelleted by centrifugation, and the supernatants were collected and subjected 
to immunoblotting analysis. 
 
2.6. Immunoblotting 
Cells growing on 6-well plates were lysed in 150 µl of non-reducing sample buffer 
(50 mM Tris-HCl pH 6.8, 2% (w/v) sodium dodecyl sulfate (SDS), 10% (v/v) glycerol, and 
0.02% (w/v) Bromophenol blue). Whole-cell lysates were then collected in Eppendorf tubes, 
boiled at 100°C for 5 min, and sonicated using Vibra-Cell ultrasonic processor (Sonic) for 20 
sec at 20% amplitude. The BCA assay (Thermo) was used to determine protein 
concentrations. 2-Mercaptoethanol (Sigma) was added to a final concentration of 6% (v/v). 
Proteins were resolved by SDS/PAGE, and then transferred to 0.45 µm nitrocellulose (NC) 
membranes (Thermo Scientific). Solutions of primary antibodies were prepared in 3% BSA 
(antibodies against phospho-proteins) or 5% milk (all other) in PBST. The following 
antibodies and dilutions were used: mouse monoclonal anti-HSP70, 1:1000, StressMarq, 
	 8	
SMC-100B; rabbit monoclonal anti-phospho-HSF1 (Ser326), 1:5000, Abcam, ab76076; 
rabbit monoclonal anti-Hsp90β, 1:5000, Abcam, ab203085; rabbit polyclonal anti-HER2, 
1:500, Millipore, 06-562; rabbit monoclonal anti-Bcl-2, 1:1000, CST, 2870; rabbit 
monoclonal anti-cytochrome c, 1:1000, CST, 11940T; rabbit monoclonal anti-CDK4, 1:1000, 
CST, 12790T; rabbit monoclonal anti-cyclin D1, 1:1000, CST, 2978T; rabbit polyclonal anti-
phospho-Rb (Ser795), 1:1000, CST, 9301T; rabbit monoclonal anti-phospho-Rb (Ser608), 
1:1000, CST, 8147T;  rabbit polyclonal anti-GAPDH, 1:5,000, Sigma, G9545; rabbit 
polyclonal anti-VDAC-1, 1:10000, Abcam, ab154856; mouse monoclonal anti-β-actin, 
1:20000, Sigma, A5441. Blocked NC membranes were incubated with the primary antibody 
solutions in 50-ml tubes at 4°C overnight, with continuous rotation. After this, the NC 
membranes were washed and incubated with the corresponding secondary antibodies 
(horseradish peroxidase (HRP)-conjugated goat anti-rabbit or goat anti-mouse antibodies, 
1:5000, BioRad). Thermo Scientific SuperSignal West Dura Extended Duration Substrate 
was used for signal development. For the experiment shown in Fig. 2, IRDye fluorescent 
dyes conjugated to secondary antibodies (GAM/GAR-800CW, 1:15000, LI-COR) were used. 
Image capture and analysis were done using the Odyssey® CLx image system and Image 
Studio software (LI-COR). 
 
2.7. Cell viability assay 
Cells (5 x 103 per well) were seeded in white flat-bottomed 96-well plates (Nunc). On 
the next day, cells were treated with 0.1% (v/v) acetonitrile (vehicle control) or increasing 
concentrations of S-4 for 24, 48 or 72 h. Four h before the end of each treatment, 10 µl of 
alamar blue dye solution (AbdSerotec) was added to the cell culture media (100 µl) within 
each well, and the plates were returned to the incubator. After 4 h, the fluorescence of the 
reduced probe was determined (ex. 560 nm/ em. 590 nm, SpectraMax M2, Molecular 
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Devices), from which the cell viability was calculated. For both cell types, the experiment 
was done on two separate occasions, each time using 8 replicate wells of cells. 
 
2.8. Cell proliferation assay 
Cell proliferation was followed for 3 days using the CellTrace™ CFSE 
(carboxyfluorescein diacetate succinimidyl ester, Thermo Scientific). Briefly, cells were 
labelled with 2.5 µM CFSE according to the manufacturer's protocol, and seeded at a density 
of 2.5 × 105 per well in 6-well plates. On	the	next	day,	cells	were	treated with 0.1% (v/v) 
acetonitrile (vehicle control) or increasing concentrations of S-4. At the indicated time points, 
the cells were collected and analyzed using BD LSRFortessa™ cell analyzer with 488 nm 
excitation and emission filters appropriate for fluorescein to measure CFSE fluorescence. 
This experiment was done twice. 
 
2.9. Cell cycle analysis 
Cells were seeded at a density of 2.5 × 105 per well in 6-well plates. On the next day, 
cells were treated with 0.1% (v/v) acetonitrile or increasing concentration of S-4 for the 
indicated time periods. After treatment, the cells were collected and fixed with 70% ethanol 
at -20℃ overnight. Cells were then washed with PBS and stained with PI (40 µg/ml) in the 
presence of RNase A (100 µg/ml) at 37°C for 30 min in the dark. The DNA content was 
detected using BD LSRFortessa™ cell analyzer. The data were analyzed in FlowJo. The 
experiment was done on three separate occasions. 
 
2.10. Data analysis 
All quantitative data are represented graphically as mean values ± 1 standard 




3.1. S-4 upregulates HSP70 in cSCC cells 
The cell line SCC IC1 was originally isolated from the primary site of a moderately 
differentiated metastatic squamous cell carcinoma that had been formed on the right temple 
of an immunocompetent 77-year-old male patient. SCC IC1 cells have well characterized 
mutational spectrum comprised of multiple UV radiation signature mutations, including 
mutations in TP53 (H179Y, R248W), NOTCH1 (N1809H), NOTCH2 (P1913S) and ERBB2 
(E1068K) (South et al., 2014). For some experiments, we also used SCC IC12 cells isolated 
from a moderately/poorly differentiated squamous cell carcinoma that had been formed on 
the left calf of an immunocompetent 87-year-old female patient. 
Monitoring the activation of transcription factor heat shock factor 1 (HSF1), the 
master regulator of the heat shock response, by the enhanced expression of its downstream 
target proteins such as heat shock protein 70 (HSP70), represents a mechanistically unbiased 
approach to screen individual compounds and chemical libraries for identification of HSP90 
inhibitors (Santagata et al., 2012). Induction of HSP70 correlates with degradation of HSP90 
client protein in peripheral blood lymphocytes and xenograft tumors (Mehta et al., 2011), and 
is used as a pharmacodynamic marker in clinical trials with HSP90 inhibitors (Shimomura et 
al., 2019). Therefore, to begin evaluating the ability of S-4 to inhibit HSP90 in SCC IC1 cells, 
we used induction of HSP70 as the first endpoint. The concentration range of S-4 was chosen 
based on a cell viability assay, which showed 20- and 50% loss of viability of SCC IC1 cells 
at 72 h post-exposure to 5- and 7.5 µM S-4, respectively (Fig. 1B). Importantly, these 
concentrations of S-4 were less toxic to cultured normal human keratinocytes (NHK) cells, 
and >90- and 80% of them were viable 72 h after 5- and 7.5 µM S-4 treatment, respectively 
(Fig. 1C).  We found that the levels of HSP70 increased in a concentration-dependent 
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manner 24 h after exposure of SCC IC1 cells to S-4 (Fig. 1D). Similar results were obtained 
in SCC IC12 cells (Supplemental Fig. 2A). A time-course experiment following exposure of 
SCC IC1 cells to 7.5 µM S-4 further showed that induction of HSP70 was time-dependent, 
and among the time points tested, was maximal at the 24-h time point (Fig. 1E). The 
induction of HSP70 was preceded by a transient increase in the levels of phosphorylated 
HSF1 at S326, a hallmark of HSF1 activation (Fig. 1E).  These results are in close agreement 
with the ability of S-4, and other structurally related sulfoxythiocarbamates, to induce HSP70 
in breast cancer cell lines (Zhang et al., 2014). 
 
3.2. S-4 binds to cysteine residues of HSP90β  
Although induction of HSP70 can be a consequence of HSP90 inhibition by 
compounds that bind to the N-terminus of the chaperone, it can also occur independently of 
HSP90. Wang et al. (Wang et al., 2017) have reported that the cellular phenotypes resulting 
from treatments with N-terminal HSP90 inhibitors (e.g. AUY922 or 17-AAG) differ from the 
phenotype caused by a knockdown of HSP90, whereas those consequent to treatments with 
C-terminal HSP90 inhibitors, phenocopy HSP90-deficient cells. We have previously shown 
that STCA forms covalent thiocarbamate adducts with cysteine residues in the middle 
domain of HSP90 (Zhang et al., 2014). To test the possibility that S-4 acts by a similar 
mechanism, we produced recombinant purified human HSP90β and incubated it with S-4 or 
its vehicle control for 2 h. Following gel purification and in-gel tryptic digestion of the 
modified protein, the resulting peptides were subjected to mass spectrometry analysis. Five 
peptides were identified in the S-4-treated sample, which were absent in the vehicle-treated 
sample (Table S1), collectively revealing that S-4 formed covalent adducts with C521, and 
C589/C590 of HSP90β.  
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Notably, C521, C589, and C590 are located in the middle domain of HSP90, 
suggesting that their modification may interfere with the ability of HSP90 to bind its co-
chaperones and/or client proteins, but not with its ATP-binding ability. It was still 
theoretically possible however that S-4 binds non-covalently to the N-terminal domain of 
HSP90. To test for this possibility, we performed an ATP-agarose pull-down of lysates from 
SCC IC1 cells that had been treated with S-4 or its vehicle control. As expected, treatment 
with the N-terminal inhibitor AUY922, which was used as positive control, abolished binding 
of HSP90 to ATP (Fig. 2). By contrast, ATP binding of HSP90 was not altered by S-4 (Fig. 
2). Because ATP binds to the N-terminal domain of HSP90, this result further confirms that 
the mode of action of S-4 is distinct from that of N-terminal inhibitors. 
 
3.3. S-4 destabilizes the HSP90 client proteins HER2 and Bcl-2 
Next, we tested the functional consequences of S-4 binding to HSP90. SCC IC1 cells 
carry mutant HER2, a tyrosine kinase oncoprotein, which has been shown to interact strongly 
with HSP90, emphasizing the importance of the chaperone for HER2 stability (Taipale et al., 
2012). Consistent with HSP90 inhibition, exposure of SCC IC1 cells to S-4 for 24 h led to a 
concentration-dependent decrease in the levels of immunologically detectable HER2 (Fig. 
3A). A time-course experiment further revealed a clear decrease of HER2 at the 8- and the 
24-h time-points (Fig. 3B). A concentration-dependent decrease in the levels of HER2 after 
exposure to S-4 was similarly observed in SCC IC12 cells (Supplemental Fig. 2B). 
Pharmacological inhibition of HSP90 has been shown to cause downregulation of another 
HSP90 client, Bcl-2 (Gallerne et al., 2013), a protein of critical importance for the integrity of 
the mitochondrial membrane (Harris and Thompson, 2000). In agreement with the 
dependence of Bcl-2 on HSP90 and HSP90 inhibition by S-4, we found that the levels of Bcl-
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2 were reduced in cells treated with 7.5 µM S-4, especially at the early (2- and 4-h) time 
points (Fig. 3C). 
 
3.4. S-4 promotes cytochrome c release 
Bcl-2 is an anti-apoptotic protein, which together with Bcl-xL, inhibits Bax-mediated 
apoptosis, promoting cell survival (Zha et al., 1996). To further explore the functional 
consequences of S-4 treatment, we considered the possibility that, by destabilizing Bcl-2, S-4 
may release its inhibitory effect on Bax. This would allow Bax to form pores on the 
mitochondrial membrane, in turn leading to cytochome c release and activation of apoptosis. 
A sub-cellular fractionation experiment showed that exposure to S-4 led to a concentration-
dependent cytochrome c release in the cytoplasm (Fig. 3D), suggesting induction of 
apoptosis via the intrinsic apoptotic pathway.  
 
3.5. S-4 causes cell cycle arrest 
Treatment with S-4 for 24 h caused inhibition in cell proliferation in a concentration-
dependent manner (Fig. 4A), and this effect was even more pronounced at 48 h post-
treatment in both SCC IC1 (Fig. 4B) and SCC IC12 (Supplemental Fig. 3A) cells. One 
possible explanation was that those cells that survived apoptosis were undergoing cell cycle 
arrest. To address this possibility, cell cycle analysis was performed. This analysis showed 
that S-4 caused a concentration-dependent arrest at the G0/1 phase of the cell cycle at 24 h 
following exposure to S-4 (Fig. 4C). Overall, from three independent experiments, at 24 h, 
compared to vehicle-treatment, the cell population in G0/1 was increased by 2.1-fold (P = 
0.05) and 2.8-fold (P = 0.036) after treatment with 5- or 7.5 µM S-4, respectively (Fig. 4D). 
Similar results were obtained in SCC IC12 cells (Supplemental Fig. 3B). 
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During early G1, the transcription factor E2F is inhibited by interaction with 
retinoblastoma susceptibility protein Rb (Fig. 5A). Activation of the cyclin D-CDK4/6 
protein complex results in the phosphorylation of Rb at multiple sites, which then releases 
E2F, in turn activating the transcription of genes that allow G1-S phase progression (Knudsen 
and Knudsen, 2008). Importantly, E2F was identified as a key transcriptional driver in the 
early stages of the development of cSCC in both humans and mice (Chitsazzadeh et al., 2016). 
Both CDK4 and cyclin D1 are HSP90 client proteins (Vaughan et al., 2006). Consistent with 
HSP90 inhibition, the levels of CDK4 and cyclin D1 decreased in a time-dependent manner 
in S-4-treated cells (Fig. 5B). In agreement with the decreased levels of CDK4 and cyclin D1, 
the levels of phosphorylated Rb at S608 and S795 were also lower in S-4-treated cells (Fig. 
5B). Together, these experiments suggest that S-4 causes destabilization of cyclin D1 and 




A large number of HSP90 inhibitors have been developed, and several have been 
tested in clinical trials (Jhaveri et al., 2012). Most have demonstrated limited clinical efficacy 
and unacceptable adverse events, such as ocular toxicities that are likely caused by 
photoreceptor cell death consequent to sustained HSP90 inhibition in the retina (Aguila et al., 
2014; Zhou et al., 2013). A recent clinical trial in patients with advanced solid tumors with 
the orally-administered pyrazolo[3,4- b]pyridine derivative TAS-116 has identified specific 
dosing regimens with promising safety and efficacy profiles, forming the basis for the current 
testing of this HSP90 inhibitor in patients with non-small cell lung cancer, gastrointestinal 
stromal tumors, and HER2-positive breast cancer (Shimomura et al., 2019). 
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Following from our previous findings that sulfoxythiocarbamate derivatives induce 
transcription factor Nrf2 (Ahn et al., 2010) and inhibit HSP90 and the proliferation of breast 
cancer cells (Zhang et al., 2014), in this study, we investigated the mechanism(s) by which 
the sulfoxythiocarbamate S-4 compromises the viability of cancer cells using two patient-
derived primary cSCC cell lines. Based on the current results, we propose a model, which is 
summarized in Fig. 6. S-4 inhibits HSP90, causing depletion of its client proteins, including 
Bcl-2, cyclin D1 and CDK4. Depletion of Bcl-2 allows Bax to form pores on the 
mitochondrial membrane, triggering cytochrome c release. Depletion of the HSP90 clients 
cyclin D1 and CDK4 by S-4 does not allow phosphorylation of Rb and the release of E2F and 
prevents G1-S cell cycle progression. Together, these processes lead to compromised cell 
viability. 
This model is based on our new findings that treatment with S-4 decreases the levels 
of Bcl-2, cyclin D1 and CDK4, all of which are well-established HSP90 clients, and the 
known functions of these proteins in apoptosis and the cell cycle. It should be noted however 
that S-4 is not a selective inhibitor of HSP90, and other potential mechanisms could also be 
contributing to the observed effects. By virtue of its sulfhydryl reactivity, S-4 may also bind 
to other cellular proteins, similarly to the closely related sulfoxythiocarbamate alkyne 
(STCA) (Ahn et al., 2010). Indeed, S-4 activates transcription factor Nrf2, as evidenced by 
the increase in the levels of the classical Nrf2-target protein, NAD(P)H:quinone 
oxidoreductase 1 (NQO1) (Zhang et al., 2014). Importantly, Nrf2 activation by compounds of 
this type requires lower concentrations than the concentrations that inhibit HSP90/induce 
HSP70 (Zhang et al., 2011) as Keap1 is endowed with highly reactive cysteine sensors 
(Dinkova-Kostova et al., 2002). Pharmacologic Nrf2 activation results in comprehensive 
multi-organ cytoprotection, including protection of the retina (Gao and Talalay, 2004; Pitha-
Rowe et al., 2009; Tanito et al., 2005), and therefore could counteract some of the negative 
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consequences of HSP90 inhibition. Thus, the ability of S-4 to both activate Nrf2 and inhibit 
HSP90 offers the advantage of protecting normal cells and tissues, whilst causing cell cycle 
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Fig. 1. S-4 induces HSP70.  (A) Chemical structure of S-4. (B,C) Viability of SCC IC1 cells 
(B) and normal human keratinocyte (NHK) cells (C) that had been left untreated, or had been 
treated with vehicle (0.1% acetonitrile) or S-4 (2.5-, 5- or 7.5 µM) for the indicated periods of 
time. *, p<0.05 relative to vehicle-treated cells (Student’s t-test). (D) Immunoblotting 
analysis for HSP70 in SCC IC1 cells that had been exposed to increasing concentrations of S-
4 for 24 h. GAPDH served as the loading control. (E) Immunoblotting analysis for HSP70 
and phosphorylated HSF1 (at S326) in cells that had been exposed to S-4 (7.5 µM) for 
increasing periods of time. β-actin served as the loading control. Results are representative of 
2 independent experiments. 
 
Fig. 2. S-4 does not interfere with the ability of HSP90β  to bind ATP. SCC IC1 cells were 
exposed for 24 h to acetonitrile (0.1%), S-4 (7.5 µM in 0.1% acetonitrile), DMSO (0.1%), or 
AUY922 (0.1 µM in 0.1% DMSO), lysed and subjected to ATP pull-down using ATP-
agarose beads. The levels of HSP90β, HSP70 and β-actin were determined by 
immunoblotting. Results are representative of 2 independent experiments.  
 
Fig. 3. S-4 destabilizes the HSP90 client proteins HER2 and Bcl-2.  (A,B) Immunoblotting 
analysis for HER2 in cells that had been exposed to increasing concentrations of S-4 for 24 h 
(A) or to 7.5 µM of S-4 for the indicated periods of time (B). (C) Immunoblotting analysis 
for Bcl-2 in cells that had been exposed to S-4 (7.5 µM) for the indicated periods of time. The 
band in the red square corresponds to Bcl-2; the faster-migrating band is a non-specific 
protein. (D) Immunoblotting analysis for cytochrome c in the cytoplasmic fraction of cells 
that had been exposed to increasing concentrations of S-4 for 8 h. β-actin served as the 
loading control. The absence of detectable VDAC-1 served as evidence for the absence of 
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mitochondrial contamination in the purified cytoplasmic fraction. In all experiments, 
acetonitrile (0.1%) served as the vehicle control and β-actin served as the loading control. 
Immunoblots are representative of 2 independent experiments. 
 
Fig. 4. S-4 causes cell cycle arrest.  (A, B) Flow cytometry analysis of cells	that	had	been	
labeled with CFSE and treated with vehicle (0.1% acetonitrile) or increasing concentrations 
of S-4 for either 24- (A) or 48- (B) h. (C) Cell cycle analysis of cells that had been left 
untreated, or treated with vehicle (0.1% acetonitrile) or S-4 (5- or 7.5 µM) for the indicated 
periods of time. Results are representative of 3 independent experiments. (D) Combined 
results of cell cycle analysis following treatment with vehicle (0.1% acetonitrile) or S-4 (5- or 
7.5 µM) for 24 h. P = 0.05 for cells treated with 5 µM S-4 compared to vehicle-treated cells; 
P = 0.036 for cells treated with 7.5 µM S-4 compared to vehicle-treated cells (Student’s t-
test). 
 
Fig. 5. S-4 causes depletion of the HSP90 client proteins CDK4 and cyclin D1, and 
inhibition of phosphorylation of the Rb protein. (A) The cyclin D-CDK4/6 protein 
complex phosphorylates Rb, which releases E2F to activate the transcription of genes that 
allow G1-S phase progression. (B) Immunoblotting analysis for CDK4, cyclin D1, and Rb 
protein  phosphorylated at S608 and S795 in cells that had been exposed to S-4 (7.5 µM) for 
the indicated periods of time. β-actin served as the loading control. In B, CDK4 was detected 
on the lower section of the same membrane shown in Fig. 1E, whereas HSP70 was detected 
using the membrane upper section; Cyclin D1 was detected on the lower section of the same 
membrane shown in Fig. 1E, whereas pHSF1(S326) was detected using the membrane upper 
section; pRb(S795) was detected on the lower section of the same membrane shown in Fig. 
3B, whereas HER2 was detected on the membrane upper section, and thus each of these two 
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blots share the same β-actin loading control. Immunoblots are representative of 2 
independent experiments. 
 
Fig. 6. Proposed model for the mechanism by which S-4 decreases the viability of SCC 
IC1 cells.  S-4 inhibits HSP90, causing depletion of its client proteins, including Bcl-2, 
cyclin D1 and CDK4. The decrease in Bcl-2 allows Bax to form pores on the mitochondrial 
membrane, triggering cytochrome c release, suggesting apoptosis. Depletion of the HSP90 
clients cyclin D1 and CDK4 prevents phosphorylation of Rb and the release of E2F, 
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Table S1. Modified peptides identified by liquid chromatography-mass spectrometry 









Peptide sequence Modifications 
2702.1883 2701.2049 45.33 LVSSPCCIVTSTYGWTANMER Carbamidomethyl (C);  
S-4 (C) 
2717.2013 2717.1998 35.75 LVSSPCCIVTSTYGWTANMER Carbamidomethyl (C);  
S-4 (C);  
Oxidation (M) 
2717.2176 2717.1998 27.18 LVSSPCCIVTSTYGWTANMER Carbamidomethyl (C);  
S-4 (C);  
Oxidation (M) 
2717.2522 2717.2467 27.61 GFEVVYMTEPIDEYCVQQLK S-4 (C) 







Fig S1. Identity and purity of S-4. 
(A) 1H-NMR spectrum showing S-4 and traces of residual volatile solvents, ethyl acetate 
and dichloromethane 
 
1H-NMR (CDCl3) δ 7.58 (t, J = 8.4, 4H), 7.45 (q, J = 6.6, 2H), 7.39-7.16(m, 8H), 4.92-4.56 
(m, 2H), 3.76-3.02 (m, 6H), 2.70-2.63 (m, br, 2H), 2.55 (d, J = 1.6, 3H), 1.85-1.74 (br, 4H); 
13C-NMR (CDCl3) δ 169.30, 168.86, 141.71, 141.50, 140.54, 140.38, 138.56, 138.49, 134.59, 
134.09, 129.15, 129.12, 129.10, 129.09, 129.05, 128.97, 128.92, 128.07, 128.03, 128.01, 
127.93, 127.84, 127.30, 127.19, 127.1553.89, 53.79, 53.31, 53.28, 53.14, 51.32, 51.30, 49.53, 
49.50, 48.07, 48.03, 45.19, 45.13, 38.88, 38.84, 28.92, 28.23, 28.13, 26.27, 26.21, 20.11, 


























































































Time Area Height Area% 
7.365 1227 193 0% 
7.625 2148 243 0% 
8.114 15459 1707 1% 
8.415 4862 579 0% 
8.655 2200107 225668 94% 
9.119 1813 354 0% 
9.304 4919 763 0% 
9.596 7510 817 0% 
9.847 13320 1552 1% 
10.393 17863 2039 1% 
10.85 6480 805 0% 
13.688 45637 2241 2% 
14.205 19360 786 1% 
 











































Fig S2. S-4 induces HSP70 and destabilizes the HSP90 client protein HER2 in SCC 
IC12 cells.  Immunoblotting analysis for HSP70 (A) and HER2 (B) in cells that had been 
exposed to increasing concentrations of S-4 for 24 h. β-Actin served as the loading control, 







Fig S3. S-4 decreases cell viability and causes cell cycle arrest in SCC IC12 cells.   
(A) Flow cytometry analysis of SCC IC12 cells	that	had	been	labeled with CFSE and 
treated with vehicle (0.1% acetonitrile) or increasing concentrations of S-4 for 48 h. (B) Cell 
cycle analysis of cells that had been left untreated, or treated with vehicle (0.1% acetonitrile) 
or S-4 (1.25-, 2.5-, 5-, 7.5-, 10- or 15 µM) for 24 h. Results are representative of 2 
independent experiments. 
 
 
	
